Isentin^®

Linagliptin

Description
Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an
endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduce hepatic glucose production. By increasing and prolonging active incretin levels, Linagliptin increases insulin release and decreases glucagon levels in the circulation in a
glucose-dependent manner.

Indication
As monotherapy:
l For patients inadequately controlled by diet and exercise alone and for whom Metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.
As combination therapy:
l In combination with Metformin when diet and exercise plus Metformin alone do not provide adequate glycaemic control.
l In combination with a Sulphonylurea and Metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.
l In combination with Insulin with or without Metformin, when this regimen alone, with diet and exercise, does not provide
adequate glycaemic control.

Supply
Isentin® Tablet 5 mg: Each box contains 2x10’s tablets in Alu-Alu blister pack.